Uroxatral and Zolpidem tartrate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Uroxatral (alfuzosin hydrochloride) and Zolpidem tartrate (zolpidem tartrate). Common drug interactions include headache among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Uroxatral and Zolpidem tartrate. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Uroxatral?

Uroxatral has active ingredients of alfuzosin hydrochloride. It is often used in prostate examination abnormal. eHealthMe is studying from 3,461 Uroxatral users. Check the latest studies of Uroxatral.

What is Zolpidem tartrate?

Zolpidem tartrate has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 32,177 Zolpidem tartrate users. Check the latest studies of Zolpidem tartrate.



On Jul, 26, 2026

25 people who take Uroxatral and Zolpidem tartrate together, and have interactions are studied.

Uroxatral and Zolpidem tartrate drug interactions.

What are the common drug interactions of Uroxatral and Zolpidem Tartrate, by gender? *:

female:

  1. Headache (pain in head)
  2. Atelectasis (partial or complete collapse of the lung)
  3. Back pain
  4. Cardiac flutter (abnormal heart rhythm)
  5. Chills (felling of cold)
  6. Coma (state of unconsciousness lasting more than six hours)
  7. Dizziness
  8. Dysphagia (a condition in which swallowing is difficult or painful)
  9. Epistaxis (bleed from the nose)
  10. Gait disturbance

male:

  1. Pneumonia
  2. Blood creatinine increased
  3. Renal failure acute (rapid kidney dysfunction)
  4. Thrombocytopenia (decrease of platelets in blood)
  5. Haemorrhage (bleeding)
  6. Rash
  7. Apnoea (suspension of external breathing)
  8. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  9. Brain injury
  10. Cold sweat

What are the common drug interactions of Uroxatral and Zolpidem Tartrate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Chronic kidney disease
  2. Renal impairment (severely reduced kidney function)
  3. Asthenia (weakness)
  4. Disturbance in attention
  5. Fatigue (feeling of tiredness)
  6. Joint swelling
  7. Nocturia (the need to get up in the night to urinate)
  8. Peripheral swelling
  9. Pruritus (severe itching of the skin)
  10. Anxiety

50-59:

  1. Headache (pain in head)
  2. Angioneurotic oedema (swelling that occurs just beneath the surface of the skin or mucous membranes)
  3. Atelectasis (partial or complete collapse of the lung)
  4. Back pain
  5. Burning sensation
  6. Cardiac flutter (abnormal heart rhythm)
  7. Chills (felling of cold)
  8. Coma (state of unconsciousness lasting more than six hours)
  9. Dizziness
  10. Dysphagia (a condition in which swallowing is difficult or painful)

60+:

  1. Pneumonia
  2. Blood creatinine increased
  3. Renal failure acute (rapid kidney dysfunction)
  4. Thrombocytopenia (decrease of platelets in blood)
  5. Haemorrhage (bleeding)
  6. Rash
  7. Apnoea (suspension of external breathing)
  8. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  9. Brain injury
  10. Cold sweat

What are the existing conditions these people have? *

  1. Pain: 7 people, 28.00%
  2. High Blood Pressure: 6 people, 24.00%
  3. Micturition Disorder (disease of passing urine): 5 people, 20.00%
  4. Asthma: 4 people, 16.00%
  5. Lung Cancer - Non-Small Cell (lung cancer): 4 people, 16.00%
  6. Diabetes: 4 people, 16.00%
  7. Heart Palpitations (feelings or sensations that your heart is pounding or racing): 4 people, 16.00%
  8. Multiple Myeloma (cancer of the plasma cells): 3 people, 12.00%
  9. Infection: 3 people, 12.00%
  10. Inflammation: 3 people, 12.00%

* Approximation only. Some reports may have incomplete information.

Do you take Uroxatral and Zolpidem tartrate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Uroxatral and Zolpidem tartrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Uroxatral:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zolpidem tartrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Uroxatral and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zolpidem tartrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on alfuzosin hydrochloride and zolpidem tartrate (the active ingredients of Uroxatral and Zolpidem tartrate, respectively), and Uroxatral and Zolpidem tartrate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: